MedPath

epoetin alfa

Generic Name
epoetin alfa
Clinical Trials
Related News

A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Phase 3
Terminated
Conditions
Anemia
Interventions
First Posted Date
2007-01-17
Last Posted Date
2011-12-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
260
Registration Number
NCT00422513

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Phase 2
Completed
Conditions
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Anemia
Lymphoproliferative Disorder
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Procedure: fatigue assessment and management
Procedure: quality-of-life assessment
First Posted Date
2006-12-28
Last Posted Date
2017-02-10
Lead Sponsor
Mayo Clinic
Target Recruit Count
239
Registration Number
NCT00416624
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)

Phase 4
Completed
Conditions
Anemia
First Posted Date
2006-11-22
Last Posted Date
2010-04-06
Lead Sponsor
Ortho Biotech, Inc.
Target Recruit Count
289
Registration Number
NCT00401869

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Completed
Conditions
Anemia
Neoplasms
Interventions
First Posted Date
2006-11-14
Last Posted Date
2012-11-06
Lead Sponsor
Janssen-Cilag B.V.
Target Recruit Count
1927
Registration Number
NCT00398749

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Phase 2
Completed
Conditions
Neoplasms
Anemia
First Posted Date
2006-10-16
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
57
Registration Number
NCT00388336

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Phase 2
Terminated
Conditions
Anemia
Neoplasms
Cancer
Interventions
First Posted Date
2006-10-11
Last Posted Date
2013-07-19
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
235
Registration Number
NCT00386152

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

Phase 2
Completed
Conditions
Acute ST Elevation Myocardial Infarction
Interventions
First Posted Date
2006-09-20
Last Posted Date
2017-05-09
Lead Sponsor
National Institute on Aging (NIA)
Target Recruit Count
223
Registration Number
NCT00378352
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

🇺🇸

Cornell University, New York, New York, United States

🇺🇸

Duke University, Durham, North Carolina, United States

and more 13 locations

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Phase 3
Completed
Conditions
Prostate
Carcinoma
First Posted Date
2006-08-15
Last Posted Date
2010-04-27
Lead Sponsor
Janssen-Ortho Inc., Canada
Target Recruit Count
56
Registration Number
NCT00364455

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Phase 3
Completed
Conditions
Anemia
Kidney Failure
Left Ventricular Hypertrophy
First Posted Date
2006-08-15
Last Posted Date
2011-02-01
Lead Sponsor
Janssen-Ortho Inc., Canada
Target Recruit Count
172
Registration Number
NCT00364260

A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.

Phase 3
Terminated
Conditions
Anemia
Neoplasms
First Posted Date
2006-07-10
Last Posted Date
2011-05-19
Lead Sponsor
Ortho Biotech Products, L.P.
Target Recruit Count
98
Registration Number
NCT00350090
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy